BioCardia
125 Shoreway Road, Suite B
San Carlos , California 94070
United States
Phone: (650) 226-0120
Fax: (650) 631-3731
[email protected]

Related Content

BioCardia Releases Primary Endpoint Results of Open Label Roll-in Cohort of CardiAMP Cell Therapy in Chronic Myocardial Ischemia Trial.
News | Cardiac Rehabilitation
BioCardia Releases Primary Endpoint Results of Open Label Roll-in Cohort of CardiAMP Cell Therapy in Chronic Myocardial Ischemia Trial

Sept. 18, 2025 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for treating cardiovascular and ...

Home September 19, 2025
arrow
BioCardia, CART-Tech Partner to Develop, Commercialize Heart3D Fusion Imaging for Interventional Cardiology
News | Cardiac Imaging
BioCardia, CART-Tech Partner to Develop, Commercialize Heart3D Fusion Imaging for Interventional Cardiology

Aug. 13, 2025 — BioCardia, Inc., a provider of cellular and cell-derived therapeutics for treating cardiovascular and ...

Home August 15, 2025
arrow
BioCardia CardiAMP
News | Cardiac Rehabilitation
Trial Results Show Autologous Cell Therapy Improves Survival, QOL and Reduces Cardiac Events in Distressed Heart Failure Patients

March 31, 2025 -— BioCardia, Inc. recently announced two-year outcomes from the double-blind randomized placebo ...

Home April 01, 2025
arrow
BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, reported it has submitted a 510(k) for approval of its patented Morph DNA Steerable Introducer Sheath
News | EP Lab
BioCardia Submits for FDA Approval of Morph DNA Steerable Introducer Product Family

July 31, 2024 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of ...

Home July 31, 2024
arrow
BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today that the confirmatory Phase 3 trial of its autologous CardiAMP cell therapy product candidate for patients with ischemic heart failure of reduced ejection fraction (HFrEF) has commenced enrollment in the United States
News | Cardiovascular Clinical Studies
Patient Enrollment Commenced in Pivotal Phase 3 Trial of CardiAMP Cell Therapy for the Treatment of Ischemic Heart Failure

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
arrow
Patent No: 12,036,371 titled “Method of Accessing the Left Atrium with a Multi-Directional Steerable Catheter,”
News | EP Lab
BioCardia Announces United States Patent Issuance on Morph DNA Multi-Directional Steerable Catheter Transseptal Application

July 17, 2024 — BioCardia, Inc., a company focused on cellular and cell-derived therapeutics for the treatment of ...

Home July 17, 2024
arrow
ProtheraCytes
News | Cardiovascular Clinical Studies
CellProthera and BioCardia Collaborate on Successful Phase II Trial of ProtheraCytes for the Treatment of Acute Myocardial Infarction

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
arrow
Radial artery delivery is a means by which cardiac catheters are advanced through a blood vessel in a patient’s wrist to treat the heart
News | Heart Failure
BioCardia Announces United States Patent Issuance on Intramyocardial Delivery of Cell Aggregates to the Heart Including Minimally Invasive Radial Artery Approach

June 7, 2024 — BioCardia, Inc., a company focused on cellular and cell-derived therapeutics for the treatment of ...

Home June 07, 2024
arrow
The primary endpoint results of the open label roll-in cohort of the CardiAMP Cell Therapy in Chronic Myocardial Ischemia Trial
News | Cardiovascular Clinical Studies
BioCardia’s CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes

May 2, 2024 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular ...

Home May 02, 2024
arrow
Partnership targets heart failure, the leading cause of death and a condition with limited treatment options
News | Heart Failure
BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership

March 15, 2024 — BioCardia, Inc. , a biotechnology company focused on advancing late-stage cell therapy interventions ...

Home March 15, 2024
arrow
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now